Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

Regulatory T cells (T(REGs)) control the key aspects of tolerance and play a role in the lack of antitumor immune responses. Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system. Although a previous study demonstrated that CY reduces the number of T(REGs), the mechanism involved in this process has yet to be defined. In this report, it is established that low-dose CY not only decreases cell number but leads to decreased functionality of T(REGs). CY treatment enhances apoptosis and decreases homeostatic proliferation of these cells. Expression of GITR and FoxP3, which are involved in the suppressive activity of T(REGs), is down-regulated after CY administration, though the level of expression varies depending on the time studied. This is the first report demonstrating that CY, in addition to decreasing cell number, inhibits the suppressive capability of T(REGs). The relevance of the loss of suppressor functionality and the changes in gene expression are further discussed.

[1]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[2]  H. Waldmann,et al.  Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[4]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[5]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[6]  J. Abrams,et al.  Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[8]  M. Oz,et al.  Intravenous Pulse Administration of Cyclophosphamide Is an Effective and Safe Treatment for Sensitized Cardiac Allograft Recipients , 2002, Circulation.

[9]  M. Byrne,et al.  CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. , 2002, Immunity.

[10]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.

[11]  A. Rudensky,et al.  Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo , 2002, Nature Immunology.

[12]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[13]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[14]  E. Jaffee,et al.  Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. , 2001, Cancer research.

[15]  M. Rajeevan,et al.  Copyright © American Society for Investigative Pathology and the Association for Molecular Pathology Validation of Array-Based Gene Expression Profiles by Real-Time (Kinetic) RT-PCR , 2022 .

[16]  D. Galas,et al.  Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse , 2001, Nature Genetics.

[17]  E. Shevach.  Suppressor T cells: Rebirth, function and homeostasis , 2000, Current Biology.

[18]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[19]  K. Scott,et al.  Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  M. Remberger,et al.  Improved survival after bone marrow transplantation for early leukemia using busulfan–cyclophosphamide and individualized prophylaxis against graft‐versus‐host disease: a long‐term follow‐up , 1999, Clinical transplantation.

[21]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[22]  F. Otsuka,et al.  Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. , 1999, Journal of immunology.

[23]  Guo-liang Yu,et al.  Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand* , 1999, The Journal of Biological Chemistry.

[24]  A. Gurney,et al.  Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR , 1999, Current Biology.

[25]  M. Toda,et al.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.

[26]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[27]  C. Riccardi,et al.  A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Miles,et al.  Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[29]  S. Morse,et al.  T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. , 1996, Journal of autoimmunity.

[30]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[31]  T. Juji,et al.  Suppressive effect of cyclophosphamide on the progression of lethal graft-versus-host disease in mice--a therapeutic model of fatal post-transfusion GVHD. , 1994, Therapeutic immunology.

[32]  M. Glaser.  Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. , 1979, Cellular immunology.

[33]  K. Nomoto,et al.  Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice. , 1979, Clinical and experimental immunology.

[34]  I. T. Young.  Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. , 1977, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[35]  A. Starzinski-Powitz,et al.  Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes , 1977, The Journal of experimental medicine.

[36]  J. Turk,et al.  Reversal by cyclophosphamide of tolerance in contact sensitization. Tolerance induced by prior feeding with DNCB. , 1975, Immunology.